文献速递炎症性肠病

抗白介素-6抗体治疗克罗恩病的随机试验与开放标签扩展研究(ANDANTE I 和 II)

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II).
PubMed 文献 · Gut · 2017-12-15

ANDANTE I 为平行分组、剂量探索、双盲试验,纳入抗肿瘤坏死因子治疗应答不足的成人克罗恩病患者,随机接受安慰剂或 PF-04236921 10、50、200 mg 皮下注射。PF-04236921 50 mg 组第 8 周和第 12 周 CDAI-70 应答率显著高于安慰剂,第 12 周 CDAI 缓解率分别为 27.4% 和 10.9%。开放标签扩展研究中 191 例接受治疗,常见不良事件包括克罗恩病加重、腹痛和鼻咽炎。

要点

  • PF-04236921 50 mg 组第 8 周 CDAI-70 应答率 49.3% vs 安慰剂组 30.6%(P<0.05)。
  • PF-04236921 50 mg 组第 12 周 CDAI-70 应答率 47.4% vs 安慰剂组 28.6%(P<0.05)。
  • 第 12 周 CDAI 缓解率 PF-04236921 50 mg 组 27.4% vs 安慰剂组 10.9%(差值 16.5%;P<0.05)。

核心结论

  • PF-04236921 50 mg 可在抗肿瘤坏死因子治疗失败的难治性中重度克罗恩病患者中诱导临床应答和缓解。
  • 研究中观察到胃肠道脓肿和穿孔,为未来临床开发中需特别关注的问题。

研究设计与样本

  • ANDANTE I 为平行分组、剂量探索、双盲试验,含 4 周筛选期和 12 周治疗期;诱导治疗后患者进入 28 周随访或 48 周开放标签扩展研究(OLE)并再随访 28 周。
  • 纳入确诊克罗恩病且抗肿瘤坏死因子治疗应答不足的成人患者。
  • 诱导研究计划将 249 例患者按 1:1:1:1 随机分配至安慰剂或 PF-04236921 10、50、200 mg 皮下注射(第 1 天和第 28 天);实际 247 例随机并接受治疗。
  • 200 mg 剂量因另一项研究(NCT01405196)的安全性发现而终止,未纳入主要疗效分析。
  • OLE 研究给予 PF-04236921 50 mg 每 8 周一次、最多 6 剂,随后 28 周随访;191 例受试者接受治疗。

主要发现

  • 第 8 周 CDAI-70 应答率 PF-04236921 50 mg 组为 49.3%,安慰剂组为 30.6%(P<0.05)。
  • 第 12 周 CDAI-70 应答率 PF-04236921 50 mg 组为 47.4%,安慰剂组为 28.6%(P<0.05),达到主要终点。
  • 第 12 周 CDAI 缓解率 PF-04236921 50 mg 组为 27.4%,安慰剂组为 10.9%(差值 16.5%;P<0.05)。
  • 两项研究中常见的治疗中出现的不良事件和严重不良事件包括克罗恩病加重、腹痛和鼻咽炎。

关键数值与推荐

  • 主要终点为第 12 周 CDAI-70 应答率,PF-04236921 50 mg 组 47.4% vs 安慰剂组 28.6%(P<0.05)。
  • 第 12 周 CDAI 缓解率 PF-04236921 50 mg 组 27.4% vs 安慰剂组 10.9%(差值 16.5%;P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 200 mg 剂量因另一项研究(NCT01405196)的安全性发现而终止,未纳入主要疗效分析。
  • 研究中观察到胃肠道脓肿和穿孔,为未来临床开发中需特别关注的问题。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported. DESIGN: Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up. RESULTS: 247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn's Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis. CONCLUSIONS: PF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development. TRIAL REGISTRATION NUMBER: NCT01287897 and NCT01345318.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 2017. PMID: 29247068. doi:10.1136/gutjnl-2017-314562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。